Novo Nordisk A/S: CagriSema demonstrates superior weight loss in adults with obesity or overweight and type 2 diabetes in the REDEFINE 2 trial
Novo Nordisk announced headline results from REDEFINE 2, a phase 3 trial in the global REDEFINE programme. REDEFINE 2 is a 68 ...
Medical Dialogues32m
CagriSema demonstrates superior weight loss in adults with obesity, type 2 diabetes in REDEFINE 2 trial: Novo Nordisk
Denmark: CagriSema has demonstrated superior weight loss in adults with obesity or overweight and type 2 diabetes in the REDEFINE 2 trial, Novo Nordisk said in a release.The headline results ...
PharmiWeb2d
Novo Nordisk A/S: CagriSema demonstrates superior…
Novo Nordisk announced headline results from REDEFINE 2, a phase 3 trial in the global REDEFINE programme. REDEFINE 2 is a 68-week efficacy and safety trial investigating once-weekly subcutaneous ...
Healio3d
CagriSema confers 15.7% weight loss at 68 weeks for adults with obesity, type 2 diabetes
Adults with obesity and type 2 diabetes receiving once-weekly combination cagrilintide 2.4 mg and semaglutide 2.4 mg lost ...
Novo Nordisk reports REDEFINE 2 trial of CagriSema achieved primary endpoint
Novo Nordisk (NVO) announced headline results from REDEFINE 2, a phase 3 trial in the global REDEFINE program. REDEFINE 2 is a 68-week efficacy ...
Pharmabiz2d
Novo Nordisk announces results from REDEFINE 2 trial of CagriSema in people with obesity and type 2 diabetes
Bagsværd, Denmark Wednesday, March 12, 2025, 12:00 Hrs [IST] ...
Finanznachrichten3d
Novo Nordisk A/S: CagriSema demonstrates superior weight loss in adults with obesity or overweight and type 2 diabetes in the REDEFINE 2 trial
REDEFINE 2 is a 68-week efficacy and safety trial investigating once-weekly subcutaneous CagriSema (a fixed dose combination of cagrilintide 2.4 mg and semaglutide 2.4 mg) compared to placebo.
Novo Nordisk's Combo Drug CagriSema Shows 16% Weight Reduction In Second Phase 3 Trial
Novo Nordisk A/S (NYSE:NVO) announced headline results from the REDEFINE 2 phase 3 trial in the global REDEFINE program. REDEFINE 2 is a 68-week efficacy and safety trial investigating once-weekly ...
Benzinga.com3d
Novo Nordisk's Combo Drug CagriSema Shows 16% Weight Reduction In Second Phase 3 Trial
In the REDEFINE 2 trial, CagriSema led to 15.7% weight loss after 68 weeks, compared to 3.1% with placebo, with 89.7% achieving at least 5% Novo Nordisk plans to seek regulatory approval for ...